Polydrug Laboratories Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 2.04 Cr
as on 26-07-2024
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 55.33 Cr
as on 26-07-2024
- Revenue -33.99%
(FY 2023)
- Profit -45.18%
(FY 2023)
- Ebitda -314.18%
(FY 2023)
- Net Worth 11.26%
(FY 2023)
- Total Assets 11.87%
(FY 2023)
About Polydrug Laboratories
The Corporate was formerly known as Polydrug Laboratories India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 2.04 Cr.
The company has closed loans amounting to ₹55.33 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Punit Thakrar and Bina Thakrar serve as directors at the Company.
- CIN/LLPIN
U24231MH2004PTC147729
- Company No.
147729
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2004
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Lower Parel, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Polydrug Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Punit Thakrar  | Managing Director | 28-Jul-2004 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bina Thakrar | Director | 01-Dec-2010 | Current |
Financial Performance of Polydrug Laboratories.
Polydrug Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 33.99% decrease. The company also saw a substantial fall in profitability, with a 45.18% decrease in profit. The company's net worth Soared by an impressive increase of 11.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Polydrug Laboratories?
In 2023, Polydrug Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 16 Feb 2013 | ₹3.50 Cr | Satisfied |
Tamilnad Mercantile Bank Limited Creation Date: 12 Feb 2013 | ₹1.46 Cr | Satisfied |
Tamilnad Mercantile Bank Limited Creation Date: 24 Apr 2012 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Polydrug Laboratories?
Polydrug Laboratories has a workforce of 1 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Polydrug Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Polydrug Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
